Capital expenditure increased 124.6%
Capital expenditure changed +124.6% from the comparable as-filed period.
$505,000→$1.1M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →RDDT financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development increased 17.6%
Research & development changed +17.6% from the comparable as-filed period.
$196.6M→$231.3M3 prior comparisons
Stock-based compensation increased 13.3%
Stock-based compensation changed +13.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$89.1M→$101.0M3 prior comparisons
Capex / revenue moved 4 bp higher
Capex / revenue changed +4 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
0.10%→0.14%3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.